Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors

Alexa B Schrock,1 Russell Madison,1 Mark Rosenzweig,2 Justin M Allen,2 Rachel L Erlich,2 Siao-Yi Wang,3 Tarek Chidiac,4 Vodur Suresh Reddy,5 Jonathan W Riess,6 Ahmet Ersin Yassa,6 Abdur Shakir,7 Vincent A Miller,1 Brian M Alexander,1 Jeffrey Venstrom,1 Kimberly McGregor,1 Siraj M Ali1 1Foundation Me...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Schrock AB, Madison R, Rosenzweig M, Allen JM, Erlich RL, Wang SY, Chidiac T, Reddy VS, Riess JW, Yassa AE, Shakir A, Miller VA, Alexander BM, Venstrom J, McGregor K, Ali SM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	alk rearrangement inversion deletion genomic profiling targeted therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/6880b7b522c94af394d70bd26157b13e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6880b7b522c94af394d70bd26157b13e
record_format	dspace
spelling	oai:doaj.org-article:6880b7b522c94af394d70bd26157b13e2021-12-02T09:04:30ZPatients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors1179-2728https://doaj.org/article/6880b7b522c94af394d70bd26157b13e2020-04-01T00:00:00Zhttps://www.dovepress.com/patients-with-nsclcs-harboring-internal-inversions-or-deletion-rearran-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Alexa B Schrock,1 Russell Madison,1 Mark Rosenzweig,2 Justin M Allen,2 Rachel L Erlich,2 Siao-Yi Wang,3 Tarek Chidiac,4 Vodur Suresh Reddy,5 Jonathan W Riess,6 Ahmet Ersin Yassa,6 Abdur Shakir,7 Vincent A Miller,1 Brian M Alexander,1 Jeffrey Venstrom,1 Kimberly McGregor,1 Siraj M Ali1 1Foundation Medicine, Department of Clinical Development, Cambridge, MA, USA; 2Foundation Medicine, Department of Translational Oncology and Clinical Reporting, Cambridge, MA, USA; 3Loyola University Medical Cancer, Department of Hematology and Oncology, Maywood, IL, USA; 4Zangmeister Cancer Center, Department of Hematology and Oncology, Columbus, OH, USA; 5Cancer Care Specialists, Department of Hematology and Oncology, Reno, NV, USA; 6UC Davis Comprehensive Cancer Center, Department of Hematology and Oncology Sacramento, CA, USA; 7Sarah Bush Lincoln Health System, Department of Medical Oncology, Mattoon, IL, USACorrespondence: Alexa B SchrockFoundation Medicine, 150 Second Street, Cambridge, MA 02141, USATel +1617-418-2200Email aschrock@foundationmedicine.comBackground: ALK fusions are targetable drivers in non-small-cell lung cancer (NSCLC). However, patients with NSCLC harboring ALK rearrangements without a fusion partner identified in DNA have also been shown to respond to ALK inhibitors. We aimed to characterize complex ALK variants that may predict sensitivity to multiple approved ALK inhibitors.Methods: Comprehensive genomic profiling (CGP) of DNA isolated from formalin‐fixed paraffin‐embedded (FFPE) tumor tissue or blood-based circulating tumor DNA was performed for 39,159 NSCLC patients during routine clinical care. For a subset of cases, RNA sequencing was performed, and prior ALK test results and clinical treatment information were collected from treating physicians.Results: We queried the Foundation Medicine NSCLC database and identified ALK internal inversions, as well as internal deletions, as the sole ALK rearrangements in 6 (0.02%) and 3 (0.01%) of cases, respectively. In cases with ALK internal inversions, RNA testing identified an EML4-ALK fusion in 2/2 cases evaluated, and 3/3 patients treated with ALK inhibitors had durable responses. A single patient with an ALK internal deletion and clinical data available responded to multiple ALK inhibitors. RNA data available for a subset of non-NSCLC cases suggest that ALK internal deletions removing a portion of the N-terminus are drivers themselves and do not result in ALK fusions. Fluorescence in situ hybridization (FISH) results were inconsistent for both classes of DNA events.Conclusion: Rare internal inversions of ALK appear to be indicative of ALK fusions, which can be detected in RNA, and response to ALK inhibitors in patients with NSCLC. In contrast, ALK internal deletions are not associated with ALK fusions in RNA but likely represent targetable drivers themselves. These data suggest that CGP of DNA should be supplemented with immunohistochemistry or RNA-based testing to further resolve these events and match patients to effective therapies.Keywords: ALK rearrangement, inversion, deletion, genomic profiling, targeted therapySchrock ABMadison RRosenzweig MAllen JMErlich RLWang SYChidiac TReddy VSRiess JWYassa AEShakir AMiller VAAlexander BMVenstrom JMcGregor KAli SMDove Medical Pressarticlealk rearrangementinversiondeletiongenomic profilingtargeted therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 11, Pp 33-39 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	alk rearrangement inversion deletion genomic profiling targeted therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	alk rearrangement inversion deletion genomic profiling targeted therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Schrock AB Madison R Rosenzweig M Allen JM Erlich RL Wang SY Chidiac T Reddy VS Riess JW Yassa AE Shakir A Miller VA Alexander BM Venstrom J McGregor K Ali SM Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
description	Alexa B Schrock,1 Russell Madison,1 Mark Rosenzweig,2 Justin M Allen,2 Rachel L Erlich,2 Siao-Yi Wang,3 Tarek Chidiac,4 Vodur Suresh Reddy,5 Jonathan W Riess,6 Ahmet Ersin Yassa,6 Abdur Shakir,7 Vincent A Miller,1 Brian M Alexander,1 Jeffrey Venstrom,1 Kimberly McGregor,1 Siraj M Ali1 1Foundation Medicine, Department of Clinical Development, Cambridge, MA, USA; 2Foundation Medicine, Department of Translational Oncology and Clinical Reporting, Cambridge, MA, USA; 3Loyola University Medical Cancer, Department of Hematology and Oncology, Maywood, IL, USA; 4Zangmeister Cancer Center, Department of Hematology and Oncology, Columbus, OH, USA; 5Cancer Care Specialists, Department of Hematology and Oncology, Reno, NV, USA; 6UC Davis Comprehensive Cancer Center, Department of Hematology and Oncology Sacramento, CA, USA; 7Sarah Bush Lincoln Health System, Department of Medical Oncology, Mattoon, IL, USACorrespondence: Alexa B SchrockFoundation Medicine, 150 Second Street, Cambridge, MA 02141, USATel +1617-418-2200Email aschrock@foundationmedicine.comBackground: ALK fusions are targetable drivers in non-small-cell lung cancer (NSCLC). However, patients with NSCLC harboring ALK rearrangements without a fusion partner identified in DNA have also been shown to respond to ALK inhibitors. We aimed to characterize complex ALK variants that may predict sensitivity to multiple approved ALK inhibitors.Methods: Comprehensive genomic profiling (CGP) of DNA isolated from formalin‐fixed paraffin‐embedded (FFPE) tumor tissue or blood-based circulating tumor DNA was performed for 39,159 NSCLC patients during routine clinical care. For a subset of cases, RNA sequencing was performed, and prior ALK test results and clinical treatment information were collected from treating physicians.Results: We queried the Foundation Medicine NSCLC database and identified ALK internal inversions, as well as internal deletions, as the sole ALK rearrangements in 6 (0.02%) and 3 (0.01%) of cases, respectively. In cases with ALK internal inversions, RNA testing identified an EML4-ALK fusion in 2/2 cases evaluated, and 3/3 patients treated with ALK inhibitors had durable responses. A single patient with an ALK internal deletion and clinical data available responded to multiple ALK inhibitors. RNA data available for a subset of non-NSCLC cases suggest that ALK internal deletions removing a portion of the N-terminus are drivers themselves and do not result in ALK fusions. Fluorescence in situ hybridization (FISH) results were inconsistent for both classes of DNA events.Conclusion: Rare internal inversions of ALK appear to be indicative of ALK fusions, which can be detected in RNA, and response to ALK inhibitors in patients with NSCLC. In contrast, ALK internal deletions are not associated with ALK fusions in RNA but likely represent targetable drivers themselves. These data suggest that CGP of DNA should be supplemented with immunohistochemistry or RNA-based testing to further resolve these events and match patients to effective therapies.Keywords: ALK rearrangement, inversion, deletion, genomic profiling, targeted therapy
format	article
author	Schrock AB Madison R Rosenzweig M Allen JM Erlich RL Wang SY Chidiac T Reddy VS Riess JW Yassa AE Shakir A Miller VA Alexander BM Venstrom J McGregor K Ali SM
author_facet	Schrock AB Madison R Rosenzweig M Allen JM Erlich RL Wang SY Chidiac T Reddy VS Riess JW Yassa AE Shakir A Miller VA Alexander BM Venstrom J McGregor K Ali SM
author_sort	Schrock AB
title	Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
title_short	Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
title_full	Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
title_fullStr	Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
title_full_unstemmed	Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
title_sort	patients with nsclcs harboring internal inversions or deletion rearrangements of the alk gene have durable responses to alk kinase inhibitors
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/6880b7b522c94af394d70bd26157b13e
work_keys_str_mv	AT schrockab patientswithnsclcsharboringinternalinversionsordeletionrearrangementsofthealkgenehavedurableresponsestoalkkinaseinhibitors AT madisonr patientswithnsclcsharboringinternalinversionsordeletionrearrangementsofthealkgenehavedurableresponsestoalkkinaseinhibitors AT rosenzweigm patientswithnsclcsharboringinternalinversionsordeletionrearrangementsofthealkgenehavedurableresponsestoalkkinaseinhibitors AT allenjm patientswithnsclcsharboringinternalinversionsordeletionrearrangementsofthealkgenehavedurableresponsestoalkkinaseinhibitors AT erlichrl patientswithnsclcsharboringinternalinversionsordeletionrearrangementsofthealkgenehavedurableresponsestoalkkinaseinhibitors AT wangsy patientswithnsclcsharboringinternalinversionsordeletionrearrangementsofthealkgenehavedurableresponsestoalkkinaseinhibitors AT chidiact patientswithnsclcsharboringinternalinversionsordeletionrearrangementsofthealkgenehavedurableresponsestoalkkinaseinhibitors AT reddyvs patientswithnsclcsharboringinternalinversionsordeletionrearrangementsofthealkgenehavedurableresponsestoalkkinaseinhibitors AT riessjw patientswithnsclcsharboringinternalinversionsordeletionrearrangementsofthealkgenehavedurableresponsestoalkkinaseinhibitors AT yassaae patientswithnsclcsharboringinternalinversionsordeletionrearrangementsofthealkgenehavedurableresponsestoalkkinaseinhibitors AT shakira patientswithnsclcsharboringinternalinversionsordeletionrearrangementsofthealkgenehavedurableresponsestoalkkinaseinhibitors AT millerva patientswithnsclcsharboringinternalinversionsordeletionrearrangementsofthealkgenehavedurableresponsestoalkkinaseinhibitors AT alexanderbm patientswithnsclcsharboringinternalinversionsordeletionrearrangementsofthealkgenehavedurableresponsestoalkkinaseinhibitors AT venstromj patientswithnsclcsharboringinternalinversionsordeletionrearrangementsofthealkgenehavedurableresponsestoalkkinaseinhibitors AT mcgregork patientswithnsclcsharboringinternalinversionsordeletionrearrangementsofthealkgenehavedurableresponsestoalkkinaseinhibitors AT alism patientswithnsclcsharboringinternalinversionsordeletionrearrangementsofthealkgenehavedurableresponsestoalkkinaseinhibitors
_version_	1718398248025063424

Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors

Ejemplares similares